Genmab AS and development partner Janssen Pharmaceutical Cos. (a Johnson & Johnson company) have ended Phase II development for Darzalex (daratumumab) monotherapy in two non-Hodgkin's lymphoma indications after a mid-trial review revealed poor results for overall response rates. A third NHL indication has also been dismissed because of a lack of data due to slow patient recruitment.
Critical eyes will now shift to upcoming data for the drug in first-line multiple myeloma, which are expected in the...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)